Grifols, S.A. (GRFS) Cash Flow Statement

The OCF/NI ratio has ranged from a negative 7.70 in 2024Q1 to a high of 17.04 in 2024Q2, indicating that operating cash flow is heavily influenced by working capital movements rather than core profitability. In 2026Q2, net income of $154M translated to $227M in operating cash flow, but a $100M working capital outflow suggests that collections and inventory timing are distorting the conversion. Investors should monitor whether the company can sustain cash generation without relying on favorable working capital swings, as the thin net margin of 8.2% leaves little room for error.

The FCF margin has been volatile, ranging from -12.5% to 21.0% over the past ten quarters, with the most recent quarter showing a sharp decline from the prior quarter's 15.1% to 5.8%. This volatility appears tied to working capital swings and capex timing, as capex increased to $119M in 2026Q2 from $60M in 2025Q2. The trajectory suggests that while the company is generating positive FCF, it has not achieved the consistent, high-margin cash generation seen in some peers, and the flat revenue growth of 0.2% YoY limits the potential for organic FCF expansion.

The capex-to-revenue ratio has more than tripled over the past two years, from 1.7% in 2024Q2 to 6.4% in 2026Q2, suggesting that the company is investing more heavily in its plasma collection network and manufacturing capacity. While this could support future growth, it also pressures near-term free cash flow, as seen in the 2026Q2 FCF margin of 5.8%. Given the high fixed costs of the plasma business, investors should assess whether this increased capital intensity is necessary to maintain the asset base or represents a strategic expansion that will yield returns over time.

The working capital line has been the most volatile component of operating cash flow, with swings of over $400M between quarters, which masks the underlying cash generation of the business. In 2026Q2, a $100M working capital outflow offset the $227M operating cash flow, reducing FCF to $108M. This pattern suggests that the company's cash conversion is heavily dependent on the timing of collections, inventory build-up, and payables, which may be influenced by the 7-to-12-month plasma processing cycle. Investors should monitor whether management can smooth these swings through better working capital management, as the current volatility complicates forecasting and may indicate operational inefficiencies.

The cash flow statement shows minimal dividends and no buybacks over the past ten quarters, with the only notable outflows being acquisitions, particularly the $1.6 billion in 2024Q4. This suggests that management is prioritizing debt reduction over shareholder returns, consistent with the recent divestment of the Shanghai RAAS stake. The lack of buybacks and dividends may indicate that the company is conserving cash to address its leverage, which remains a key concern given the debt-to-equity ratio of 1.15. Investors should monitor whether this capital allocation strategy will lead to a sustainable reduction in leverage and improved financial flexibility.

While cumulative operating cash flow has outpaced net income, the pattern is not consistent, with some quarters showing OCF/NI ratios above 5 and others negative. This divergence appears to be driven by working capital swings rather than sustainable operational improvements, as the company's net margin remains thin at around 5-8%. The cumulative gap may indicate that the company is generating cash from balance sheet changes rather than core profitability, which warrants caution when assessing the sustainability of cash flows. Investors should focus on the quality of earnings, as the reported net income may not fully reflect the cash-generating capacity of the underlying plasma business.